Navigation Links
GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
Date:2/9/2011

Phase 1, Phase 2, and Phase 3 clinical trials of experimental HIV vaccines. The goals of these clinical research studies are to evaluate the safety and the ability of new vaccines to induce immune responses capable of protecting individuals from HIV infection and/or controlling disease. The AVRC has contributed to the clinical testing of the GeoVax HIV vaccines in HIV uninfected individuals.

About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are s
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
2. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
3. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
4. GeoVax Labs Engages The Investor Relations Group
5. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
6. GeoVax Labs, Inc. Plans Public Offering
7. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
8. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
9. GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update
10. GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting
11. Chuck Panozzo, Founder of Rock Band Styx, Joins GeoVax Labs, Inc. as an Advocate for Its HIV/AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Touro University California,s College ... selected as the recipient of a $150,000 grant by ... the University to increase research and classroom space on ... technology for the study of health sciences, and will ... needs and interests of our students," said Shelley ...
(Date:7/31/2014)... , July 31, 2014 Hovione today ... has successfully passed a pre-approval inspection by the ... carried out by the FDA Consumer Safety Officer, Ms. ... on 21 st July and concluded on the 25 ... with the principles and guidelines of Good Manufacturing Practices (GMP) ...
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
Breaking Medicine Technology:Touro University California Garners Grant From Long Foundation 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2
... MVP Marketing + Design, Inc., a Minneapolis-based, branding, communications ... of eleven American Graphic Design Awards for selected client ... online and retail promotions created for three separate divisions ... (Skin and Wound Care, Office Supplies and Stationery Products), ...
... announces the approval of CollaGUARD surgical adhesion barrier for ... surgery. The product will be launched this year through ... to seek approval in a number of additional territories, ... and to initiate the studies required for registration in ...
Cached Medicine Technology:MVP Sweeps 2011 American Graphic Design Awards with Nine of 11 Wins for 3M Projects 2Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier 2Innocoll Announces European Approval for CollaGUARD®, Surgical Adhesion Barrier 3
(Date:7/31/2014)... David Kekich, anti-aging icon and CEO of ... that the acceptance of his revolutionary approach of ... algorithms and then screening thousands of compounds against ... , “It took longer than I thought and ... said Kekich. "Client acceptance is exploding, early clinical ...
(Date:7/31/2014)... Malaysia (PRWEB) July 31, 2014 ... mymobileuni.com, entered into strategic alliance with Dr. Lawrence ... and provide content to http://www.mymobileuni.com its ... Channel http://www.mymobileuni.net/mu3/health.php will include courses, e-books ... who want to learn, re-skill or up-skill themselves ...
(Date:7/31/2014)... 2014 (HealthDay News) -- The virus that causes cold sores ... the absence of symptoms, according to a new study. ... the cells of people infected with the virus. This explains ... and why others get them only occasionally. The authors said ... "We thought when the disease was dormant, it ...
(Date:7/31/2014)... MO (PRWEB) July 31, 2014 Saint ... with an Excellence Through Insight award for Overall Patient ... and Systems (CG-CAHPS) database in multiple categories by HealthStream, ... their commitment to excellence in patient care. To qualify ... been a patient satisfaction-tracking client of HealthStream in 2013, ...
(Date:7/31/2014)... OK (PRWEB) July 31, 2014 Shiitakes ... As in the recipe for Quick-Fix Spaghetti Sauce below, ... second-most consumed mushroom worldwide, valued for their deep flavor ... mushrooms. They absorb flavors of the foods they're cooked ... texture and offer high-protein, low-fat nutrition. Shiitakes are rich ...
Breaking Medicine News(10 mins):Health News:MaxLife Solution™ Expands Distribution Globally for Breakthrough Anti-Inflammatory Support Supplement – InflaGene™ 2Health News:MyMobileUniversity and Fortech International Form Strategic Alliance That Will Enhance the Global Health and Medical Channel on Its Website 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2Health News:Saint Luke’s Health System Physicians and Clinics Earn Excellence through Insight Awards for Overall Patient Experience in the CG-CAHPS Database 2Health News:Saint Luke’s Health System Physicians and Clinics Earn Excellence through Insight Awards for Overall Patient Experience in the CG-CAHPS Database 3Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 2Health News:Quick Fixin’ Summertime Meals with Shiitake Mushrooms -- Bring ‘em Home and Grow Your Own 3
... encouraging results for the long-term efficacy of a meningitis ... effective when given to infants older than 5 months.// ... the United Kingdom in 1999. While the short-term effectiveness ... a study looking at the data from the four ...
... risk of developing dementia later in life, a healthy diet ... conducted, researchers followed nearly 1,500 participants for more than 20 ... were twice as likely to develop dementia later in life. ... in middle age were six-times more likely to develop dementia ...
... suggests that older patients can avoid the risk of stroke by ... who ate fish; one to four// times a week had ... atrial fibrillation), than those who ate fish less than once a ... greater benefit – as their risk was lowered by 31%. However ...
... on active baby boomers. Arthritis followed by knee replacement surgery ... middle-aged Americans. Now a new technique offers hope for active ... feet, crouching and clicking, kneeling and directing. His glamour photography ... lifeblood," he says. "If they don't work, I don't work." ...
... it safe for people with heart disease to travel by ... on // issues involving air travel for heart patients -- ... on implantable automatic defibrillators and pacemakers, the need for preflight ... dangerous blood clot that can arise in the leg when ...
... heart attack patients fare better after having a procedure to ... results // from a recent study. The study, conducted in ... a group of about 870 men and about 160 women ... heart attack. While both sexes had about the same success ...
Cached Medicine News:
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Colorimetric Assay of Plasminogen Activity by STA© Analyzers....
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
Calibration Plasmas for Assaysof Unfractionated Heparins (UFH) using the Anti-Xa Method on STA© Analyzers....
Medicine Products: